ArticleJournal of cancer research and clinical oncology2026
Basal cell subsets, as biomarker to predict the therapeutic effect of neoadjuvant therapy for esophageal carcinoma.
Article in Journal of cancer research and clinical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundAt present, neoadjuvant therapy before surgery has important application prospects in esophageal carcinoma (ESCA). However, there is still a lack of effective biomarkers to predict the prognosis of neoadjuvant therapy for ESCA.
methodWe analyzed tumor and paired adjacent tissues from 22 stage II-IV ESCA patients (21 ESCC and 1 esophageal adenosquamous carcinoma, EASC) who received neoadjuvant chemo-immunotherapy (anti-PD-1 antibody plus platinum and albumin-bound paclitaxel) at Tangdu Hospital. The R package "CellChat" was used to analyze cell-cell communication of single-cell RNA sequencing (scRNA-seq) data. Basal cell subsets were identified and quantified using "Seurat", and their correlations with pathological response were calculated. Differentially expressed genes (DEGs) were identified using "Seurat", and 27 non-redundant DEGs were further annotated using the TIMER database.
resultIt was found that the intercellular communication between basal cells and other cells was gradually weakened in incomplete pathological response (IPR), major pathological response (MPR), and pathological complete response (pCR). Specifically, Basal3 and Basal8 subsets exhibited strong correlations with pCR, while the Basal7 subgroup was highly correlated with IPR. Further TIMER analysis of the top 10 genes in these subsets indicated that ATF3 and JUN impacted ESCA survival.
conclusionIn summary, our study found cellular characteristics of different subsets of basal cells in ESCA patients treated with neoadjuvant therapy, and found that the subsets associated with poor efficacy were Basal7, and the subsets associated with good efficacy were Basal3 and Basal8, which provided possible biomarkers for neoadjuvant therapy of esophageal carcinoma in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.